- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Enrollment open, Real-world evidence, Real-world effectiveness, Real-world: LURBICLIN: RW Effectiveness of Lurbinectedin in Extensive Stage SCLC (clinicaltrials.gov) - Jun 30, 2022 P=N/A, N=200, Recruiting, Trial completion date: Sep 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Not yet recruiting --> Recruiting
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz, Tecentriq (atezolizumab) / Roche
Tincture of Time (Main Room) - May 25, 2022 - Abstract #Macula2022Macula_17; The offending drug was atezolizumab (Tecentriq), a humanized IgG1 monoclonal antibody targeted against programmed cell death ligand 1 (PD-L1)...From a systemic standpoint, her metastatic CCS has continued to respond to combination treatment on clinical trial with lurbinectedin/irinotecan...This case underscores the importance of recognizing the full spectrum of checkpoint inhibitor-associated ocular ir-AEs. Objective: To describe the long-term clinical findings and visual prognosis in a rare form of checkpoint inhibitor-associated retinopathy.
- |||||||||| Journal: The 2021 Marine Pharmacology and Pharmaceuticals Pipeline. (Pubmed Central) - May 14, 2022
In 2021, new marine-derived drugs were approved by FDA, as well as in Australia and China. The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Trial completion date, Trial initiation date, Trial primary completion date, Metastases: Lurbinectedin in Patients With Advanced Gastrointestinal Malignancies With DNA Repair Mutations (clinicaltrials.gov) - May 12, 2022 P2, N=19, Not yet recruiting, The clinical development of marine-derived drugs remained very robust and active with several advancing to Ph III, Ph II and entering at Ph I. Trial completion date: Mar 2026 --> Aug 2026 | Initiation date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2025 --> Aug 2025
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Journal: Accelerated approval requirements for lurbinectedin. (Pubmed Central) - May 7, 2022 Trial completion date: Mar 2026 --> Aug 2026 | Initiation date: Mar 2022 --> Aug 2022 | Trial primary completion date: Mar 2025 --> Aug 2025 No abstract available
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Journal: Lurbinectedin-induced thrombocytopenia: the role of body surface area. (Pubmed Central) - May 4, 2022 This recommendation was based on an exposure-response study, which demonstrated that patients with lower BSA had a higher incidence of thrombocytopenia. Herein we present the factors associated with BSA and thrombopoiesis, which may have contributed to the observed relationship.
- |||||||||| Zepzelca (lurbinectedin) / PharmaMar, Jazz
Review, Journal: Treatment of Small Cell Lung Cancer with Lurbinectedin: A Review. (Pubmed Central) - Apr 29, 2022 Lurbinectedin is known to act by inhibiting the active transcription of encoding genes, thereby bringing about the suppression of tumour related macrophages with an impact on tumour atmosphere. Lurbinectedin has emerged as a potential drug candidate for the treatment of small cell lung cancer (SCLC).
|